Physicians' Academy for Cardiovascular Education

ACS

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD
##SCROLLER_ITEMS_FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

10' education - Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI :Patient cases based on real world data

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

10' education - Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew
Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.

ESC 2019 Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens
Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.

ESC 2019 Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.

Unexpected findings of superiority with a P2Y12 inhibitor in reducing outcomes in ACS patients

Literature - Sep. 1, 2019
Comparison of prasugrel with ticagrelor showed that prasugrel was superior in reducing death, MI and stroke at one year in ACS patients with and without ST-segment elevation.

ESC 2019 Comparison of prasugrel with ticagrelor showed that prasugrel was superior in reducing death, MI and stroke at one year in ACS patients with and without ST-segment elevation.

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke
Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduces ischemic endpoints, without an increased bleeding risk.

ESC 2019 Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduced ischemic endpoints as compared with ticagrelor, without an increased bleeding risk.

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills
In patients with suspected ACS, adoption of an early rule-out pathway for MI using hs-troponin reduced the length of stay, increased proportion of patients discharged by emergency department and was safe.

ESC 2019 In patients with suspected ACS, adoption of an early rule-out pathway for MI using hs-troponin reduced the length of stay, increased proportion of patients discharged by emergency department and was safe.

No mortality benefit of beta-blocker in stable CAD beyond one year after MI, according to registry data

Literature - June 24, 2019 - Sorbets E et al., - Eur Heart J. 2019
CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.

CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.

Benefits of dual COMPASS regimen also seen in patients with moderate renal dysfunction

Literature - May 21, 2019 - Fox KAA et al., - J Am Coll Cardiol. 2019

An analysis of the COMPASS trial in patients with GFR ≥60 or <60 mL/min showed consistent treatment benefit of the combination of rivaroxaban 2.5 mg bd plus aspirin, vs aspirin alone.

FDA expands indication for PCSK9 inhibitor to prevent major CV events in adults with CVD

News - May 6, 2019

The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.

Guided DAPT de-escalation therapy in PCI-treated ACS patients with diabetes vs. non-diabetes

Literature - May 1, 2019 - Hein R, et al. - EuroIntervention 2019

No interaction was observed between diabetes status, guided DAPT de-escalation therapy vs. control therapy and outcomes in ACS patients after PCI.

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Large absolute benefit with PCSK9 inhibitor in ACS patients with polyvascular disease

Literature - Mar. 27, 2019 - Jukema JW, et al. - JACC 2019

A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD
Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.